Elesclomol (STA-4783)

Catalog No.S1052

Elesclomol (STA-4783) Chemical Structure

Molecular Weight(MW): 400.5

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • BMC Genomics 2014 15(1), 263. Elesclomol (STA-4783) purchased from Selleck.

    Treatment with elesclomol inhibits cancer cell growth and induces apoptosis by increasing ROS levels. a. Cell growth of SMOV2, IGROV1, and OVCA432 ovarian cancer cells treated with elesclomol in the presence or absence of the antioxidant NAC for 72 h. Cell growth was measured using the WST-1 assay and quantified relative to DMSO treated controls.

    Oncotarget, 2016, 7(35):56933-56943. Elesclomol (STA-4783) purchased from Selleck.

  • Overexpression of GILZ favors oxidative cell death Dose-response of ROS production (HE staining) (A) or cell death (PI staining) (B) in indicated cells exposed toincreasing concentrations of elesclomol for 24 h (mean ± SD, n = 3, *p < 0.05). Alternatively, cells were treated with elesclomol for 24 h with or without pre-incubation with10 mM N-Acetyl Cysteine (NAC) for 12 h before HE staining (A) or PI staining (B) (mean ± SD, n = 3, *p < 0.05).

    Int J Biochem Cell Biol, 2017, 85:166-174. Elesclomol (STA-4783) purchased from Selleck.

    The proliferation of PC3 and LNCaP cells exposed to elesclomol at a range of concentrations for 48 h was assessed using MTT assay. Results are expressed as percentage of MTT absorbance of untreated cells at 0 h. p < .05 and p < .01 compared to untreated controls. Data are means ± SEM; n = 4.

    Int J Radiat Biol, 2017, 93(2):194-203. Elesclomol (STA-4783) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Targets
HSP70 [1]
(Cell-free assay)
In vitro

Elesclomol significantly induces the expression of heat shock stress response genes and metallothionein genes, a signature transcription profile indicative of oxidative stress in Hs294T cells. Elesclomol (100 nM) rapidly induces Hsp70 RNA levels with a 4.8-fold increase at 1 hour and a 160-fold increase at 6 hours in Ramos Burkitt's lymphoma B cells in consistent with the intracellular ROS content which increases by 20% as early as 0.5 hour and 385% at 6 hours, and the induction of Hsp70 can be blocked by antioxidants N-acetylcysteine (NAC) and Tiron pretreatment. Elesclomol increases the number of early and late apoptotic cells with 3.7- and 11-fold through the induction of oxidative stress, which can be completely blocked by NAC, while having little effect on normal cells. [1] Elesclomol significantly inhibits the cell viability of SK-MEL-5, MCF-7, and HL-60 with IC50 of 110 nM, 24 nM and 9 nM, respectively. [2] Elesclomol induces copper-dependent ROS generation and cytoxicity in yeast. Instead of working through a specific cellular protein target, Elesclomol interacts with the electron transport chain (ETC), a biologically coherent set of processes occurring in the mitochondrion, to generate high levels of ROS within the organelle and consequently cell death. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NOS-1 cell NHGxdYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXrDeYhMUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCB|Lk[2[U0xPSEQvF2= NYjucWVyW0GQR1XS
CAL-51 cell M3;JXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXvPc5VHUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF{NjDuUS=> MkDFV2FPT0WU
ABC-1 cell MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX3yZ3BWUW6qaXLpeIlwdiCxZjDoeY1idiCDQlOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzZ3IH7N MmPjV2FPT0WU
A2780 cell NH3Oc2dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NW\URWdWUW6qaXLpeIlwdiCxZjDoeY1idiCDMke4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTl2IH7N M33RfXNCVkeHUh?=
ES1 cell MknVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFm3SlFKdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|Q6KG6P NUHpNZJEW0GQR1XS
HUTU-80 cell M3KwU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MYLJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc6OSCwTR?= NFyz[ldUSU6JRWK=
NCI-H292 cell NH3F[ZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45QDZibl2= MmjlV2FPT0WU
NB69 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXXnbVdLUW6qaXLpeIlwdiCxZjDoeY1idiCQQk[5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOiCwTR?= MX;TRW5ITVJ?
ES8 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYDkT5ZHUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlMzKG6P NYDxS|BiW0GQR1XS
BCPAP cell NHq2dmRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJGJEWEGSIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zOEBvVQ>? MmLqV2FPT0WU
T-24 cell NUjRVXVvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWXJcohq[mm2aX;uJI9nKGi3bXHuJHQuOjRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkW1JI5O NWruTJBQW0GQR1XS
EW-16 cell MmWyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXHJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTF4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NUBvVQ>? NV7rZnZkW0GQR1XS
OVCAR-5 cell NEW1SpZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHfVTW9KdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh|IH7N NWXnbVZDW0GQR1XS
SF126 cell NGDuXplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvDOlNKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PSCwTR?= MUHTRW5ITVJ?
KP-4 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\LW2lvcGmkaYTpc44hd2ZiaIXtZY4hU1BvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNVchdk1? NHjrSVhUSU6JRWK=
GAMG cell NHnQVmJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVjJcohq[mm2aX;uJI9nKGi3bXHuJGdCVUdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkWxJI5O NH7JelNUSU6JRWK=
HOS cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWLJcohq[mm2aX;uJI9nKGi3bXHuJGhQWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUOgcm0> MkDNV2FPT0WU
CHL-1 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mlv2TY5pcWKrdHnvckBw\iCqdX3hckBEUExvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPFEhdk1? NWrjbnRoW0GQR1XS
AGS cell NXnrZmllT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXfhXZJIUW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlg3KG6P NVzlVWZXW0GQR1XS
MDA-MB-157 cell NXexdJV[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2xOVch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjl{IH7N NV7jR3V7W0GQR1XS
HSC-3 cell NFLK[pBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4m0[2lvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAzKG6P M17FcXNCVkeHUh?=
CAL-72 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC15MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNFIhdk1? NV;aS4tRW0GQR1XS
NBsusSR cell MoTJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUjJcohq[mm2aX;uJI9nKGi3bXHuJG5De3W|U2KgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlE{KG6P MmrGV2FPT0WU
ES7 cell MlTES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJGVUPyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUmgcm0> NHjkS3JUSU6JRWK=
H-EMC-SS cell Mn3nS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUW3dnhtUW6qaXLpeIlwdiCxZjDoeY1idiCKLVXNR{1UWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNkigcm0> NWDqXJptW0GQR1XS
NCI-H1703 cell MkjmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4OxNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO|A{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54ODDuUS=> MljqV2FPT0WU
BHT-101 cell M2fJUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2\2PGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPzJibl2= NHSyN5NUSU6JRWK=
SK-OV-3 cell MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFy4eHBKdmirYnn0bY9vKG:oIHj1cYFvKFONLV;WMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Njd3IH7N NXTxR|FFW0GQR1XS
EW-24 cell NVvDeog6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTJ2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64N{BvVQ>? NXywdIxGW0GQR1XS
PSN1 cell NInReFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NInac4tKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlg1KG6P MVjTRW5ITVJ?
OVCAR-8 cell NIDteHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWC4Zpc5UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy57OTDuUS=> NEDqe5JUSU6JRWK=
NCI-H1563 cell NX[1dlBPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NX\zRoU{UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2PjNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkGzJI5O NWLWOoZsW0GQR1XS
SW756 cell Mkn3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWPTcmVNUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e1OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTNibl2= NVHPVWtTW0GQR1XS
A375 cell MkLnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmnmTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6xOEBvVQ>? MoD2V2FPT0WU
Ca9-22 cell M2T3R2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFPYPWlKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOjVibl2= NIH3dodUSU6JRWK=
SW1990 cell NEfPOXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml7sTY5pcWKrdHnvckBw\iCqdX3hckBUXzF7OUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlMzKG6P MmnFV2FPT0WU
ES4 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1XSVGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6zPUBvVQ>? NI\hXmxUSU6JRWK=
HCE-T cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJGhETS2WIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60OUBvVQ>? MWPTRW5ITVJ?
MOLT-16 cell Mli2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVLJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlU{KG6P MXjTRW5ITVJ?
HSC-4 cell MmjUS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYDFVpNZUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQCCwTR?= Ml;MV2FPT0WU
NCI-SNU-1 cell M4DSU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV23RlJDUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtV25WNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lki2JI5O M4\n[nNCVkeHUh?=
EW-11 cell MofjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1OzV2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlkhdk1? NYLVOodEW0GQR1XS
HT-1080 cell MnjLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH;VdZBKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7IH7N NXHrS3ZlW0GQR1XS
MES-SA/Dx5 cells M{XvdmN6fG:2b4jpZ4l1gSCjc4PhfS=> NU[5T5V[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{whUUN3ME21JI5O NGnNOIIzOzl|N{m4NS=>
SW1710 cell MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3XtcGlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yPiCwTR?= MonHV2FPT0WU
EW-1 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGVYNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkK0JI5O M1vxd3NCVkeHUh?=
BV-173 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoDLTY5pcWKrdHnvckBw\iCqdX3hckBDXi1zN{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6KG6P NHXIS5NUSU6JRWK=
TE-8 cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3;UV2lvcGmkaYTpc44hd2ZiaIXtZY4hXEVvODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFEhdk1? NY\JXVZJW0GQR1XS
G-401 cell MlfKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1vTWmlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ{KG6P NYDHbZFzW0GQR1XS
KOSC-2 cell NYW4OG42T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mkf6TY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ2KG6P MoHYV2FPT0WU
HuCCT1 cell M{fVSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGh2S0OWMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOVIhdk1? NEPJZnlUSU6JRWK=
FADU cell NVXB[VJrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGTqeohKdmirYnn0bY9vKG:oIHj1cYFvKE[DRGWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlY3KG6P NXmwfG9NW0GQR1XS
MHH-ES-1 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXnJcohq[mm2aX;uJI9nKGi3bXHuJG1JUC2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU43QSCwTR?= NEe3XW1USU6JRWK=
ES3 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGnZZWhKdmirYnn0bY9vKG:oIHj1cYFvKEWVMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|khdk1? MVXTRW5ITVJ?
OVCAR-4 cell Mmq2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWL4e4l6UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NzDuUS=> M3TrZnNCVkeHUh?=
HD-MY-Z cell NIDjbZRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoLITY5pcWKrdHnvckBw\iCqdX3hckBJTC2PWT3aJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46OSCwTR?= MYLTRW5ITVJ?
human JAR cell NF73NnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MVXJcohq[mm2aX;uJI9nKGi3bXHuJGpCWiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOUegcm0> M3XpSXNCVkeHUh?=
A427 cell M1zHPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;jXXVKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlA4KG6P MnvOV2FPT0WU
697 cell NE\pSIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF\TVW9KdmirYnn0bY9vKG:oIHj1cYFvKDZ7NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNVMhdk1? MXLTRW5ITVJ?
OVCAR-3 cell MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkTXTY5pcWKrdHnvckBw\iCqdX3hckBQXkODUj2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4zKG6P M2LoTHNCVkeHUh?=
human NB14 cell NIe1[VBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFPZPZJKdmirYnn0bY9vKG:oIHj1cYFvKE6EMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY1KG6P NYXXV2V4W0GQR1XS
GB-1 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmC0TY5pcWKrdHnvckBw\iCqdX3hckBISi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj63NUBvVQ>? M2LBS3NCVkeHUh?=
COR-L105 cell NWrXNGFFT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWHJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok44PiCwTR?= NEPJfWJUSU6JRWK=
647-V cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1HK[GlvcGmkaYTpc44hd2ZiaIXtZY4hPjR5LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22Mlkhdk1? M1PUS3NCVkeHUh?=
human K5 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{T0ZmlvcGmkaYTpc44hd2ZiaIXtZY4hUzViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15IH7N NFrGZXJUSU6JRWK=
DMS-273 cell NHryO5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mn;1TY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= NWH1UJp{W0GQR1XS
UM-UC-3 cell MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHETY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4xPiCwTR?= MlPFV2FPT0WU
HEL cell MkDaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MVTJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEigcm0> M{PQVXNCVkeHUh?=
human KU-19-19 cell MoraS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXi3e3VxUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdwMEmgcm0> M3PZWnNCVkeHUh?=
MC-IXC cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHPhSmpKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOTdibl2= MVTTRW5ITVJ?
human H4 cell M3rOcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3fEWWlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15LkK1JI5O NHqxPYNUSU6JRWK=
NUGC-3 cell MkD0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NI\NTYZKdmirYnn0bY9vKG:oIHj1cYFvKE6XR1OtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzNibl2= M4DvcnNCVkeHUh?=
CHP-212 cell Mki0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7mTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{4{PCCwTR?= NEXmV4RUSU6JRWK=
human SW982 cell M3vUTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4DhZ2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlQ1KG6P NXzrOGVLW0GQR1XS
C-33-A cell Mm\zS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWXhPI9VUW6qaXLpeIlwdiCxZjDoeY1idiCFLUOzMWEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjV6IH7N NW\rcFI6W0GQR1XS
PC-3 cell M13Rcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn\mTY5pcWKrdHnvckBw\iCqdX3hckBRSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nz64PUBvVQ>? M1\vOHNCVkeHUh?=
COLO-684 cell NWTLNohvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Ml3aTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvOjFibl2= NF3z[WZUSU6JRWK=
SNU-387 cell NUHDNlN7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmTWTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvM{i3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU41QSCwTR?= MYHTRW5ITVJ?
U251 cell M1TMXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmTUTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT64OkBvVQ>? NEfQSINUSU6JRWK=
A673 cell NXz6e3BuT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHrrSolKdmirYnn0bY9vKG:oIHj1cYFvKEF4N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU43KG6P NIrYZ3VUSU6JRWK=
human T47D cell NF3UeINIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zNj63PUBvVQ>? M17EWXNCVkeHUh?=
A549 cell M1nYfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jVb2lvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUG5MlYhdk1? NYnjbJo1W0GQR1XS
PC-14 cell NEiyN4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M17keGlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yOE44OyCwTR?= M4XIN3NCVkeHUh?=
A704 cell NXjSdmx[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{TUSWlvcGmkaYTpc44hd2ZiaIXtZY4hSTdyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUK3MlQ2KG6P Mk\JV2FPT0WU
MCF7 cell MnnCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\1OoNKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zNU4{PiCwTR?= NHfmelJUSU6JRWK=
PC3 cells MWLGeY5kfGmxbjDhd5NigQ>? M1TJPWlvcGmkaYTpc44hd2ZiUFTLNU1u\WSrYYTl[EBCU1RicHjvd5Bpd3K7bHH0bY9vKGG2IGTodlMxQCC{ZYPp[JVmKGmwIHj1cYFvKFCFMzDj[YxteyCkeTDFUGlUSSxiSVO1NF0xNjFzMzFOwG0> MmLYNlE{PDF4N{W=
F-36P cells MUfQdo9tcW[ncnH0bY9vKGG|c3H5 NUjFeWdkSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGMVM3WCClZXzsd{whUUN3ME2wMlI5KM7:TR?= M3jpSFIyOzRzNke1
OCI-AML2 cells NHnPUHlRem:uaX\ldoF1cW:wIHHzd4F6 NEjZPGxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF;DTU1CVUx{IHPlcIx{NCCLQ{WwQVAvOzVizszN M37iWVIyOzRzNke1
K562 cells MnzGVJJwdGmoZYLheIlwdiCjc4PhfS=> NX;GTGZJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLOVYzKGOnbHzzMEBKSzVyPUG4JO69VQ>? MUiyNVM1OTZ5NR?=

... Click to View More Cell Line Experimental Data
In vivo Although Elesclomol (25-100 mg/kg) as a single agent shows no antitumor activity in nude mouse xenograft models of human breast cancers (MDA435, MCF7 and ZR-75-1), lung cancer (RER) or lymphoma (U937), Elesclomol substantially enhances the efficacy of chemotherapeutic agents such as paclitaxel in these models, both in terms of tumor regression and extended survival of mice. [4]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Hs294T, HSB2, and Ramos
  • Concentrations: Dissolved in DMSO at a concentration of 10 mM, final concentrations ~500 nM
  • Incubation Time: 18, or 24 hours
  • Method: Cells are treated with various concentrations of Elesclomol for 18 or 24 hours. The level of intracellular ROS is monitored using the DCFDA probe, which emits a green fluorescence on oxidation. Cell death is determined by flow cytometry of cells double stained with Annexin V/FITC and propidium iodide (PI) using a Vybrant Apoptosis assay kit.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing established MDA435 breast cancer xenograft tumors
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~100 mg/kg
  • Administration: Intravenous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 80 mg/mL (199.75 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing. 		30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 400.5
Formula

C19H20N4O2S2
CAS No. 488832-69-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we use the compound for in vivo mouse studies?

  • Answer:

    S1052 in 1% DMSO+30% polyethylene glycol+1% Tween 80 is a suspension, it is fine for oral administration. You can also dissolve S1052 in 0.5-1% CMC-Na solution and treat the mice by oral gavage.

selleck catalog

HSP (e.g. HSP90) Signaling Pathway Map

Related HSP (e.g. HSP90) Products

  • PU-H71 New

    PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.

  • KNK437 New

    KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.

  • VER155008 New

    VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.

  • Tanespimycin (17-AAG)

    Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

    Features:Displays very low toxicity toward normal cells.

  • Luminespib (AUY-922, NVP-AUY922)

    Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.

  • Ganetespib (STA-9090)

    Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.

  • Alvespimycin (17-DMAG) HCl

    Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

    Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.

  • Geldanamycin

    Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.

  • HSP990 (NVP-HSP990)

    NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

    Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.

  • Onalespib (AT13387)

    Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Tags: buy Elesclomol (STA-4783) | Elesclomol (STA-4783) supplier | purchase Elesclomol (STA-4783) | Elesclomol (STA-4783) cost | Elesclomol (STA-4783) manufacturer | order Elesclomol (STA-4783) | Elesclomol (STA-4783) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID